As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
A rapid response to a cluster of patients affected with pneumonia of unknown cause in Wuhan, China in December 2019, led to the identification, isolation and sequencing of the SARS-CoV-2. This virus belongs to the genus Betacoronavirus (family Coronaviridae), which also includes the SARS and MERS-CoVs, which caused epidemics in 2002–2003 and 2012, respectively. Infections by these viruses had higher mortality rates compared to the current COVID-19 outbreak: 9.5%, 34%, and 6.7%, respectively1,2,3.
In recent years we have witnessed the outbreaks of other “emergent” RNA viruses, including the influenza A(H1N1)pdm09 in 2009, ebola in 2014 and 2018–2019, and zika in 2016, in addition to the endemic dengue and yellow fever viral outbursts, which annually infect hundreds of thousands of patients in tropical regions4. Combined with their high mutation rates, large population sizes and fast replicative cycles, RNA viral populations quickly explore a vast number of mutational landscapes, which can lead to the emergence of new infectious viruses in humans or viruses with different pathogenic properties. In contrast with other RNA viruses, coronaviruses and other families of the Nidovirales order encode for a 3′-5′ exoribonuclease (ExoN) with proofreading activity (nsp14), which diminishes their mutation rate, and is one of the key factors that explains why they are endowed with the longest linear genomes in the RNA virosphere5.
As of today, there are no broad-spectrum antivirals available to treat the vast majority of emergent RNA viral infections. This is due to the extreme variability of RNA viral proteomes and the absence of conserved therapeutic targets at which antivirals could be aimed. Currently, the WHO is undertaking the “Solidarity clinical trial for COVID-19 treatments”, a global effort aimed at discovering an efficient treatment against the COVID-19 among those pharmacological resources that have proven to be effective in vitro or in vivo against SARS-CoV-2 and/or related viruses such as SARS and MERS coronaviruses6. The drugs being repurposed in this global effort include HIV-1 protease inhibitors Lopinavir/Ritonavir; Interferon β-1a; the anti-malarial hydroxychloroquine/chloroquine as viral entry inhibitors, and viral RdRp inhibitor Remdesivir. Furthermore, over 950 clinical trials worldwide are registered in the WHO platform as of April 17th, 2020, and results from some of them should be available soon.
The most highly conserved protein in all known RNA viruses is the viral monomeric RdRp. The coronavirus replication machinery is a large multi-subunit complex; however, the polymerase domain (nsp12) has the characteristic right-hand shape with fingers, thumb and palm subdomains, and the six conserved structural motifs (Fig. 1)7. Structural and phylogenetic analysis indicate that all known viral RdRps are monophyletic and preserve a high degree of structural conservation, in which key residues within six conserved structural motifs partake in the correct nucleotide recognition and incorporation8. Nowadays, there are several drugs that bind to the RdRp active site and that have been approved to treat other RNA viral diseases, including Favipiravir9 and Remdesivir10. This latter is an adenosine analogue, which has been shown to be efficacious preventing different coronaviral infections in mice, and viral populations lacking the ExoN activity are more sensitive to the drug11. Recently, this drug proved to be effective blocking SARS-CoV-2 infection in vitro12.
Sofosbuvir (SOF) is a nucleotide analogue targeted against the HCV polymerase, NS5B. The structure of HCV bound to SOF13 reveals that the drug binds to the active site and is incorporated into the nascent strand preventing the addition of the next nucleotide. The residues that participate in SOF binding include motif A’s D225, motif B’s S282, T287, and N291 (the latter binds to the SOF 2′-F), motif F’s K141 and R158, plus motif A’s and C’s universally conserved aspartates that coordinate the metal ions13. Previous work has shown that SOF has in vitro and/or in vivo antiviral activity against other Flaviviruses, i.e. Dengue, Zika, and the West Nile Virus14,15,16. The RdRp structural conservation extends beyond the Flaviviridae members and includes all known RNA viruses8.
Results and discussion
The multiple alignment of the SARS-CoV nsp12 sequence with distinct SARS-CoV-2 nsp12 sequences and MERS-related coronaviruses shows that the SOF-binding residues are conserved (Fig. 2a). As expected, even the most recent SARS-CoV-2 sequences present a strict conservation of the polymerase catalytic domain and the binding residues (Fig. 2a). A structural superposition of the SARS-coronavirus nsp12 with HCV NS5B bound to SOF shows that the inhibitor can be modeled into the nsp12’s active site without any steric hindrances, and that the residues that partake in SOF binding are well conserved in the SARS-coronavirus active site (Fig. 2b). As observed in Fig. 2b, some of the residues’ side-chains involved in SOF-binding and catalytic activities have different conformations in the two polymerases. This might be explained by the fact that the HCV NS5B is in an active conformation, whereas the SARS-CoV nsp12 is in its apo-form. Neither the results presented here nor a recently published independent model7 support the possibility that the conserved T680 found in coronaviruses but absent in NS5B is required for SOF binding to the RdRp active site. Detailed characterization of the interaction between T680 and SOF must await experimental analysis and/or the availability of a three-dimensional structure of SARS-CoV-2 nsp12 bound to SOF. While this manuscript was under review, very similar conclusions have been reported by Elfiky17. The work built an homology-based model of the SARS-CoV-2 nsp12 and performed molecular docking experiments to test if Sofosbuvir, as well as other nucleoside analogs, might be effective against the virus, yielding very promising results.
With the number of COVID-19 cases surpassing the 2 million and fatalities reaching over 160 000 deaths, the resources and the options being tested against the virus are increasing in a parallel way, with serious proposals of testing stem-cells and traditional Chinese medicines as antivirals18. Considering our in silico results and the work by Elfiky17, added to the fact that SOF has already been approved as a standard treatment and has a well-known safety profile19, it would be interesting to develop in vitro experiments to test its efficacy against the SARS-CoV-2 as well as its minimal inhibitory concentration as a step towards later testing in a clinical setting. Although SOF has a high barrier to resistance, several point mutations have been identified in the HCV NS5B that confer resistance to this drug in clinical settings, which may occur in the SARS-CoV-2 nsp1220. Furthermore, since the presence of the proofreading enzyme has been shown to interfere with the antiviral activity of nucleoside analogs by their removal from the nascent chain in coronaviral infections21, as suggested by the use of Remdesivir-based therapies11, it can be speculated that a SOF regime in high concentrations might circumvent the action of the ExoN and prevent the removal of the drug. The SARS-CoV-2 RdRp inhibition might represent a key step towards a control of the COVID-19 pandemic; nevertheless, the two latter aspects and previous RNA viral infections suggest that a multitargeted approach, in which different drugs target different viral proteins, might be the ultimate strategy.
From an evolutionary perspective, the highly conserved palm subdomain of viral RdRps might be the RNA viral Achilles heel. The availability of additional tertiary structures can help to understand the differences and the relatedness between viral RdRps, which, in turn, may lead to more alternatives towards the development of broad spectrum antivirals.
Materials and Methods
Coronavirus nsp12 multiple alignment
From the orf1ab polyprotein (Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1) deposited in the NCBI (NC_045512.2), we selected the nsp12 RNA-dependent RNA polymerase sequence (protein id. YP_009725307.1). A BLASTp was performed and representative sequences of current SARS-CoV-2, SARS- and MERS-related coronaviruses as well as two bat betacoronaviruses were downloaded. In order to analyze the possibility that mutations might have emerged during the four months of the COVID-19 pandemic, we downloaded sequences from samples collected in April from the GISAID platform22. The multiple alignment was performed in MEGA X23 with the ClustalW algorithm using default parameters. The multiple alignment was edited in BioEdit24, only the residues corresponding to the conserved structural motifs A-F are shown.
Structural superposition of hepatitis C virus and SARS-CoV polymerases
The structural superposition of the hepatitis C virus polymerase NS5B bound to Sofosbuvir [PDB ID: 4WTG13] with the SARS-coronavirus nsp12 [PDB ID: 6NUR7] was performed in Chimera 1.1325 using the MatchMaker26 algorithm with default parameters. The tertiary structures were edited and depicted with Chimera 1.1325.
Hui, D. S. C. & Zumla, A. Severe acute respiratory syndrome: historical, epidemiological and clinical features. Infect. Dis. Clin. N. Am. 33, 869–889 (2019).
Ashar, E. I., Hui, D. S. C., Memish, Z. A. & Zumla, A. The Middle East respiratory syndrome (MERS). Infect. Dis. Clin. N. Am. 33, 891–905 (2019).
WHO. Coronavirus disease (COVID-19) Situation dashboard – April 18th, 2020, https://covid19.who.int/ (2020).
Jácome, R. et al. A yellow flag on the horizon: the looming threat of yellow fever to North America. Int. J. Infect. Dis. 87, 143–150 (2019).
Ogando, N. S. et al. The curious case of the Nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity. Front. Microbiol. 10, 1813 (2019).
WHO. Solidarity clinical trial for the COVID-19 treatments, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (2020)
Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 cofactors. Nat. Commun. 10, 2342 (2019).
Jácome, R., Becerra, A., Ponce de León, S. & Lazcano, A. Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications. PLoS ONE 10, e0139001 (2015).
Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B. 93, 449–463 (2017).
Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys. Nature. 531, 381–385 (2016).
Agostini, M. L. et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease. mBio. 9, e00221–18 (2018).
Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., https://doi.org/10.1038/s41422-020-0282-0 (2020)
Appleby, T. C. et al. Structural basis for RNA replication by the Hepatitis C virus polymerase. Science. 347, 771–775 (2015).
Gan, C. S., Lim, S. K., Chee, C. F., Yusof, R. & Heh, C. H. Sofosbuvir as treatment against Dengue? Chem. Bio. Drug Des. 91, 448–455 (2018).
Mesci, P. et al. Blocking Zika virus vertical transmission. Sci. Rep. 8, 1218 (2018).
Dragoni, F. et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res. 175, 104708 (2020).
Elfiky, A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 148, 117477 (2020).
Maxmen, A. More than 80 clinical trials launch to test coronavirus treatment. Nature https://doi.org/10.1038/d41586-020-00444-3 (2020).
McQuaid, T., Savini, C. & Seyedkazemi, S. Sofosbuvir, a significant paradigm change in HCV treatment. J. Clin. Transl. Hepatol. 3, 27–35 (2015).
Donaldson, E. F., Harrington, P. R., O’Rear, J. J. & Naeger, L. K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61, 56–65 (2015).
Clinton Smith, E., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565 (2013).
Shu, Y., McCauley, J. GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22, https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494 (2017).
Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 35, 1547–1549 (2018).
Hall, T. A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids Symp. Ser. 41, 95–98 (1999).
Pettersen, E. F. et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Meng, E. C., Pettersen, E. F., Couch, G. S., Huang, C. C. & Ferrin, T. E. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics. 7, 339 (2006).
We are indebted to Drs. Gloria Soberón and Ricardo Hernández-Morales, and to Mr. Adrián Cruz González for their valuable bibliographic contributions.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jácome, R., Campillo-Balderas, J.A., Ponce de León, S. et al. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep 10, 9294 (2020). https://doi.org/10.1038/s41598-020-66440-9
Journal of Hepatology (2020)